68.2% of GRIFOLS revenues come from the US and Canada. Covid19 cases there seem to be decreasing. The company is delaying more and more its deadline of results for the phase III of the inmunoglobulina antiCovid-19, now until spring 2021.
If GRLS results are positive or better than expected (specially Q4 ones), I expect a jump from 21.61 to 26 in a matter of 2...
Focused on hemoderivatives (blood plasma), Grifols is great value by most of investors. Even though the company might be one day spitted by any scandal on how it is gathering the plasma in the US, americans have got a high stake on it and today it is focusing on an hyperimmune immunoglobulin with specific antibodies against the SARS-CoV-2 virus. Grifols estimated...
I think in this covid19 scenario grifols is a really good pic with the medical improvements that they are offering.
It's a safe pick so i recommend reading about this coorporation and make your own research.
